PATH-SCAN: A REPORTING TOOL FOR IDENTIFYING CLINICALLY ACTIONABLE VARIANTS

被引:0
|
作者
Daneshjou, Roxana [1 ]
Zappala, Zachary [1 ]
Kukurba, Kim [1 ]
Boyle, Sean M. [1 ]
Ormond, Kelly E. [1 ]
Klein, Teri E. [1 ]
Snyder, Michael [1 ]
Bustamante, Carlos D. [1 ]
Altman, Russ B. [1 ,2 ]
Montgomery, Stephen B. [1 ,3 ]
机构
[1] Stanford Univ, Dept Genet, Stanford, CA 94061 USA
[2] Stanford Univ, Dept Bioengn, Stanford, CA 94061 USA
[3] Stanford Univ, Dept Pathol, Stanford, CA 94061 USA
关键词
POLYMORPHISM H558R; SPLICE VARIANT; SCN5A; ASSOCIATION; EXPRESSION;
D O I
暂无
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The American College of Medical Genetics and Genomics (ACMG) recently released guidelines regarding the reporting of incidental findings in sequencing data. Given the availability of Direct to Consumer (DTC) genetic testing and the falling cost of whole exome and genome sequencing, individuals will increasingly have the opportunity to analyze their own genomic data. We have developed a web-based tool, PATH-SCAN, which annotates individual genomes and exomes for ClinVar designated pathogenic variants found within the genes from the ACMG guidelines. Because mutations in these genes predispose individuals to conditions with actionable outcomes, our tool will allow individuals or researchers to identify potential risk variants in order to consult physicians or genetic counselors for further evaluation. Moreover, our tool allows individuals to anonymously submit their pathogenic burden, so that we can crowd source the collection of quantitative information regarding the frequency of these variants. We tested our tool on 1092 publicly available genomes from the 1000 Genomes project, 163 genomes from the Personal Genome Project, and 15 genomes from a clinical genome sequencing research project. Excluding the most commonly seen variant in 1000 Genomes, about 20% of all genomes analyzed had a ClinVar designated pathogenic variant that required further evaluation.
引用
收藏
页码:229 / 240
页数:12
相关论文
共 50 条
  • [31] Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review
    Douglas, Michael P.
    Ladabaum, Uri
    Pletcher, Mark J.
    Marshall, Deborah A.
    Phillips, Kathryn A.
    GENETICS IN MEDICINE, 2016, 18 (02) : 111 - 116
  • [32] Identification of Rare Clinically Actionable Variants in KRAS, EGFR, and BRAF Using a Comprehensive Gene Panel
    Weeraratne, D.
    Lyle, S.
    Russell, M.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2018, 20 (06): : 997 - 997
  • [33] Preconception carrier screening: effect of reporting variants of unknown significance in partners of carriers with clinically significant variants
    Fridman, H.
    Behar, D.
    Carmi, S.
    Levy-Lahad, E.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 1214 - 1214
  • [34] Evaluation of somatic and germline variants in patients with small bowel adenocarcinoma reveals clinically actionable targets.
    Wei, Deng
    Liu, Si
    Li, Xiaomo
    Ma, Tonghui
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Pharmacogenetic Review: Germline Genetic Variants Possessing Increased Cancer Risk With Clinically Actionable Therapeutic Relationships
    Saugstad, Austin A.
    Petry, Natasha
    Hajek, Catherine
    FRONTIERS IN GENETICS, 2022, 13
  • [36] Identification and electronic health record incorporation of clinically actionable pharmacogenomic variants using prospective targeted sequencing
    Scherer, S.
    Qin, X.
    Sanghvi, R.
    Walker, K.
    Chiang, T.
    Muzny, D.
    Wang, L.
    Black, J.
    Boerwinkle, E.
    Weinshilboum, R.
    Gibbs, R.
    HUMAN GENOMICS, 2016, 10
  • [37] Routine Use of the FusionPlex Solid Tumor Panel in Identifying Clinically Actionable Gene Rearrangements in Lung Adenocarcinomas
    Nicka, C.
    de Abreu, F.
    Peterson, J.
    Tsongalis, G. J.
    Tafe, L. J.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2017, 19 (06): : 1034 - 1034
  • [38] Multigene Panel Testing Yields High Rates of Clinically Actionable Variants Among Patients With Colorectal Cancer
    Coughlin, Sarah E.
    Heald, Brandie
    Clark, Dana Farengo
    Nielsen, Sarah M.
    Hatchell, Kathryn E.
    Esplin, Edward D.
    Katona, Bryson W.
    JCO PRECISION ONCOLOGY, 2022, 6
  • [39] Cruxome: a powerful tool for annotating, interpreting and reporting genetic variants
    Han Q.
    Yang Y.
    Wu S.
    Liao Y.
    Zhang S.
    Liang H.
    Cram D.S.
    Zhang Y.
    BMC Genomics, 22 (1)
  • [40] Locus Reference Genomic: reference sequences for the reporting of clinically relevant sequence variants
    MacArthur, Jacqueline A. L.
    Morales, Joannella
    Tully, Ray E.
    Astashyn, Alex
    Gil, Laurent
    Bruford, Elspeth A.
    Larsson, Pontus
    Flicek, Paul
    Dalgleish, Raymond
    Maglott, Donna R.
    Cunningham, Fiona
    NUCLEIC ACIDS RESEARCH, 2014, 42 (D1) : D873 - D878